Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

“The additional findings of the Phase 3 KINECT-HD study presented in this poster demonstrate an improvement in chorea over time, with an increase in responder rates in the TMC primary endpoint, and CGI-C and PGI-C outcomes by study visit up to Week 12,” said Eiry W. Roberts, M.D., Chief Medical Officer. “Data from the KINECT-HD and the ongoing KINECT-HD2 study formed the basis for our recent supplemental new drug application (sNDA) submission to the U.S. Food and Drug Administration.”

CLICK HERE FOR FULL RELEASE